Undifferentiated pleomorphic sarcoma

From WikiMD's Wellness Encyclopedia

(Redirected from Malignant fibrous cytoma)

Pleomorphic undifferentiated sarcoma - very high mag

Undifferentiated Pleomorphic Sarcoma (UPS), formerly known as Malignant Fibrous Histiocytoma (MFH), is a type of soft tissue sarcoma that is characterized by high-grade, undifferentiated tumor cells. This condition represents a challenging aspect of oncology and pathology, given its aggressive nature and complex diagnostic criteria. UPS typically affects adults and is more common in the elderly, with a slight male predominance. It can arise in any part of the body but is most frequently found in the extremities, particularly the legs, and also in the retroperitoneum.

Etiology and Pathogenesis[edit | edit source]

The exact cause of Undifferentiated Pleomorphic Sarcoma is not well understood. However, it is believed to be associated with genetic mutations and may be influenced by previous radiation therapy or chronic lymphedema. The tumor is characterized by a heterogeneous mix of cells, including fibroblasts, myofibroblasts, and histiocytes, although these cells are poorly differentiated, making the diagnosis challenging.

Clinical Presentation[edit | edit source]

Patients with UPS may present with a painless or painful mass that has been growing over time. Symptoms are often nonspecific and can vary depending on the tumor's location. For instance, tumors in the extremities may cause swelling or a noticeable lump, while those in the retroperitoneum can lead to abdominal pain or fullness.

Diagnosis[edit | edit source]

The diagnosis of Undifferentiated Pleomorphic Sarcoma is primarily based on histological examination of the tumor tissue. Imaging studies such as MRI and CT scans are used to assess the tumor's size, location, and potential spread to other parts of the body. A definitive diagnosis, however, requires a biopsy, where a sample of the tumor is examined under a microscope by a pathologist. The histological appearance of UPS is variable, but it typically shows a mixture of spindle-shaped and pleomorphic (varied shapes and sizes) cells with high mitotic activity.

Treatment[edit | edit source]

Treatment for Undifferentiated Pleomorphic Sarcoma typically involves a combination of surgery, radiation therapy, and chemotherapy. The primary treatment is surgical resection with the aim of removing the tumor completely, often followed by radiation therapy to kill any remaining cancer cells. Chemotherapy may be used in cases where the tumor is large, has spread to other parts of the body, or is at high risk of recurrence.

Prognosis[edit | edit source]

The prognosis for patients with Undifferentiated Pleomorphic Sarcoma depends on several factors, including the size and location of the tumor, the extent of its spread at the time of diagnosis, and the patient's overall health. Generally, the prognosis is better for patients with smaller, localized tumors that can be completely removed surgically. However, UPS is an aggressive cancer that has a high risk of recurrence and metastasis, particularly to the lungs.

Prevention and Screening[edit | edit source]

There are no specific guidelines for the prevention or screening of Undifferentiated Pleomorphic Sarcoma due to its rarity and the lack of clear risk factors. However, maintaining a healthy lifestyle and avoiding known carcinogens may reduce the overall risk of developing cancer.


WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD